Table of Content

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: U.S. Injectable Contraceptives Market

4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. U.S. Injectable Contraceptives Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights
    5.1. Pipeline Analysis
    5.2. Overview of Contraceptive Usage, Mechanism of Action, Advantages, etc.
    5.3. COVID-19 Pandemic Impact on the Industry

6. U.S. Injectable Contraceptives Market Analysis and Forecast, By Product Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Product Type, 2017-2031
        6.3.1. Subcutaneous MedroxyProgesterone Acetate (MPA)
        6.3.2. Intramuscular Depot MedroxyProgesterone Acetate (MPA)
    6.4. Market Attractiveness Analysis, by Product Type

7. U.S. Injectable Contraceptives Market Analysis and Forecast, By Distribution Channel
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, By Distribution Channel, 2017-2031
        7.3.1. Hospital Pharmacies
        7.3.2. Retail Pharmacies
        7.3.3. Online Pharmacies
    7.4. Market Attractiveness Analysis, By Distribution Channel

8. Competition Landscape
    8.1. Market Player - Competition Matrix (by tier and size of companies)
    8.2. Market Share Analysis, By Company (2022)
    8.3. Company Profiles
        8.3.1. Viatris, Inc. (Mylan N.V.)
            8.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            8.3.1.2. Product Portfolio
            8.3.1.3. Financial Overview
            8.3.1.4. SWOT Analysis
            8.3.1.5. Strategic Overview
        8.3.2. Pfizer, Inc.
            8.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            8.3.2.2. Product Portfolio
            8.3.2.3. Financial Overview
            8.3.2.4. SWOT Analysis
            8.3.2.5. Strategic Overview
        8.3.3. Teva Pharmaceutical Industries Ltd
            8.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            8.3.3.2. Product Portfolio
            8.3.3.3. Financial Overview
            8.3.3.4. SWOT Analysis
            8.3.3.5. Strategic Overview



List of Figures

List of Figures

Figure 01: U.S. Injectable Contraceptives Market Value (US$ Mn) Forecast, 2017-2031

Figure 02: U.S. Injectable Contraceptives Market Value Share, by Product Type, 2022

Figure 03: U.S. Injectable Contraceptives Market Value Share, by Distribution Channel, 2022

Figure 04: U.S. Injectable Contraceptives Market Value Share Analysis, by Product Type, 2022 and 2031

Figure 05: U.S. Injectable Contraceptives Market Attractiveness Analysis, by Product Type, 2023-2031

Figure 06: U.S. Injectable Contraceptives Market (US$ Mn), by Subcutaneous MedroxyProgesterone Acetate (MPA), 2017-2031

Figure 07: U.S. Injectable Contraceptives Market (US$ Mn), by Intramuscular Depot MedroxyProgesterone Acetate (MPA), 2017-2031

Figure 08: U.S. Injectable Contraceptives Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 09: U.S. Injectable Contraceptives Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 10: U.S. Injectable Contraceptives Market (US$ Mn), by Hospital Pharmacies, 2017-2031

Figure 11: U.S. Injectable Contraceptives Market (US$ Mn), by Retail Pharmacies, 2017-2031

Figure 12: U.S. Injectable Contraceptives Market (US$ Mn), by Online Pharmacies, 2017-2031

Figure 13: U.S. Injectable Contraceptives Market Share Analysis, by Company, 2022

List of Tables

List of Tables

Table 01: U.S. Injectable Contraceptives Market Value (US$ Mn) Forecast, by Product Type, 2017-2031

Table 02: U.S. Injectable Contraceptives Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031